Between June 2011 and March 2018, 260 blood samples from 228 glioma-suspect patients that met the inclusion criteria and test-quality, were evaluated for GFAP+ monocytes (Supplementary Fig. 2A, Patient flow chart). The gene discussed is GFAP; the disease is central nervous system cancer.